Assets (12 total) 12 Total Assets
7 Approved
4 Phase 3 / Filed
1 Phase 1–2 / Early
14 Diseases
Disease: All diseases (12) Type 2 Diabetes (4) Chronic Kidney Disease (3) Atherosclerotic Cardiovascular Disease (3) Major Depressive Disorder (1) Schizophrenia (1) Bipolar Disorder (1) Bipolar Depression (1) Multiple Sclerosis (1) Systemic Lupus Erythematosus (1) Myasthenia Gravis (1) Tardive Dyskinesia (1) Huntington's Disease (1) Alzheimer's Disease (1) Inflammatory Bowel Disease (1)
Stage: All stages (12) Approved / Phase 4 (7) Phase 3 / Filed (4) Phase 2 Phase 1 / Preclinical
Quick filter: All (12) Type 2 Diabetes (4) Chronic Kidney Disease (3) Atherosclerotic Cardiovascular Disease (3) Major Depressive Disorder (1) Schizophrenia (1)
Showing 12 of 12 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Approved SGLT2 Small molecule
Type 2 Diabetes Chronic Kidney Disease
Approved Dopamine D3/D2 receptor (partial agonist) Small molecule
Major Depressive Disorder Schizophrenia Bipolar Disorder Bipolar Depression
Approved Sphingosine 1-phosphate receptor (S1PR, specifically S1P1) · S1P receptor · Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) Small molecule
Approved CD19 Monoclonal antibody
Systemic Lupus Erythematosus Myasthenia Gravis
Generalized Myasthenia Gravis Approved GLP-1/GIP receptor (dual) Peptide
Type 2 Diabetes Atherosclerotic Cardiovascular Disease
Approved HIF prolyl hydroxylase (HIF-PH1/2/3) Small molecule
Approved vesicular monoamine transporter 2 (VMAT2) Small molecule
Tardive Dyskinesia Huntington's Disease
Huntington's Disease Chorea Phase 3 Oral spherical carbon adsorbent Small molecule
Phase 3 CETP Small molecule
Type 2 Diabetes Atherosclerotic Cardiovascular Disease Alzheimer's Disease
Early Alzheimer's Disease Phase 3 Serotonin 5-HT2A receptor (antagonist / inverse agonist) Small molecule
Atherosclerotic Cardiovascular Disease
Phase 3 DPP-4 Small molecule
Phase 2 S1P receptor Small molecule
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease
Upcoming events (14 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (3) November 2026 (2) Obicetrapib Phase 2 Dyslipidemias Est. primary completion 2026-11 ·
NCT06496243 ·
CT.gov ↗ What to watch
Obicetrapib Phase 3 Atherosclerotic Cardiovascular Disease Est. primary completion 2026-11 ·
NCT05202509 ·
CT.gov ↗ What to watch
December 2026 (1) Est. primary completion 2026-12-15 ·
NCT03817502 ·
CT.gov ↗ What to watch
2027 (2) March 2027 (1) April 2027 (1) Inebilizumab Phase 2 Neuromyelitis Optica Spectrum Disorder Est. primary completion 2027-04-13 ·
NCT05549258 ·
CT.gov ↗ What to watch
2028 (4) March 2028 (1) Obicetrapib Phase 3 Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS) Est. primary completion 2028-03 ·
NCT07219602 ·
CT.gov ↗ What to watch
April 2028 (1) August 2028 (1) Inebilizumab Phase 2 Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis Est. primary completion 2028-08-06 ·
NCT06570798 ·
CT.gov ↗ What to watch
September 2028 (1) Obicetrapib Phase 2 Preclinical Alzheimer's Disease Est. primary completion 2028-09 ·
NCT07794670 ·
CT.gov ↗ What to watch
2030 (2) March 2030 (1) Inebilizumab Phase 2 Generalized Myasthenia Gravis Est. primary completion 2030-03-13 ·
NCT06987539 ·
CT.gov ↗ What to watch
August 2030 (1) Tirzepatide (Mounjaro) Phase 3 Metabolic Dysfunction-Associated Steatotic Liver Disease Est. primary completion 2030-08 ·
NCT07165028 ·
CT.gov ↗ What to watch
2031 (3) June 2031 (1) Inebilizumab Phase 2 Immunoglobulin G4-related Disease Est. primary completion 2031-06-10 ·
NCT07222553 ·
CT.gov ↗ What to watch
July 2031 (1) Inebilizumab Phase 3 Autoimmune Hepatitis, AIH Est. primary completion 2031-07-30 ·
NCT07598825 ·
CT.gov ↗ What to watch
September 2031 (1) Inebilizumab Phase 3 Glomerulonephritis, Membranous Est. primary completion 2031-09-27 ·
NCT07851220 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (16) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
5 November 2026 Topline result Vadadustat VOCAL meets its non-inferiority primary endpoint 21 September 2026 Approval Obicetrapib European Commission approves Ubeslo (obicetrapib) EU, EC · NewAmsterdam Pharma and Menarini Group ·
Source ↗ 28 August 2026 Approval tirzepatide FDA approves Mounjaro to reduce cardiovascular risk in type 2 diabetes June 2026 Topline result Vadadustat VOICE interim analysis met the predefined stopping criteria (non-inferiority and superiority on the primary composite endpoint) 12 February 2026 Approval Inebilizumab European Commission approves UPLIZNA for generalized myasthenia gravis 22 December 2025 Topline result Valbenazine (Ingrezza) KINECT-DCP Phase 3 misses primary and key secondary endpoints 11 December 2025 Approval Inebilizumab FDA approves UPLIZNA for generalized myasthenia gravis December 2025 Topline result Valbenazine KINECT-DCP Phase 3 (NCT05206513) did not meet its primary or key secondary endpoints 18 August 2025 Filing accepted Obicetrapib EMA validates obicetrapib MAA 3 April 2025 Approval Inebilizumab FDA approves UPLIZNA for IgG4-RD 27 February 2025 Topline result Valbenazine KINECT-PRO Phase 4 top-line patient-reported outcome data The 12 most recent of 16 past events are shown.
Financial reports No financial reports recorded.